Physician profile
Stratton Grisoli
NPI 1447678610
$5,933.97
in general payments reported to CMS, 2019-2025
29 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $303 · 2021: $577 · 2022: $635 · 2023: $1,259 · 2024: $1,212 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,196.17 |
| Education | $223.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.10 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $706.58 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $606.65 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $528.73 | 2019-2025 | |
| Pfizer INC. | $397.26 | 2019-2025 | |
| Leo Pharma INC. | $394.93 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $293.39 | 2019-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $246.07 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $184.37 | 2019-2025 | Absorica Ld, Winlevi |
| Incyte Corporation | $179.66 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $164.73 | 2019-2025 | Aklief, Oracea, Epsolay |
| Novartis Pharmaceuticals Corporation | $152.88 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.15 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.84 | 2019-2024 | Cabtreo, Jublia, Arazlo |
| Almirall LLC | $138.67 | 2021-2025 | Klisyri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $131.22 | 2022-2025 | Otezla |
| Lilly USA, LLC | $110.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Revance Therapeutics, INC. | $90.02 | 2024 | Daxxify |
| Vyne Pharmaceuticals INC. | $79.20 | 2020 | |
| Journey Medical Corporation | $64.12 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.78 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $52.35 | 2023-2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $31.84 | 2023-2025 | Ycanth |
| Allergan, INC. | $30.84 | 2021 | |
| Merz North America, INC. | $28.94 | 2019 | |
| Dermavant Sciences, INC. | $20.87 | 2023 | Vtama |
| Dermira, INC. | $17.60 | 2020 | |
| Aclaris Therapeutics, INC. | $15.52 | 2019 | |
| Celgene Corporation | $14.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stratton Grisoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.